CHEST 2025: INSIDE LOOK
Marriott Marquis, Grand Horizon ABC
Sponsored by National Jewish Health
Supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Interstitial lung disease (ILD) encompasses a diverse group of more than 200 pulmonary disorders, each characterized by complex inflammatory and fibrotic processes that lead to progressive lung damage. Diagnostic delays—often exceeding 12 months—allow for the progression of irreversible fibrosis, which significantly worsens patient outcomes. Common misconceptions around management of complex ILD can further complicate patients getting the care they need.
In this CME breakfast symposium, presented by National Jewish Health, a panel of leading pulmonologists and rheumatologists specializing in ILD will address medical myths and misconceptions around diagnosis and management of fibrosing ILDs, including idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), and systemic autoimmune rheumatic disease-associated interstitial lung disease (SARD-ILD). In this interactive session, myths will be “busted” with current evidence, guidelines, and data on current and emerging treatments.
1.0 CME/MOC
This symposium is not supported, endorsed, or accredited by the American College of Chest Physicians.
Ayodeji Adegunsoye, MD, MSc, PhD, FCCP
University of Chicago Medicine
Pulmonary & Critical Care
Assistant Professor of Medicine
Chicago, Illinois
University of Chicago Medicine
Pulmonary & Critical Care
Scientific Director, Interstitial Lung Disease Program
Chicago, Illinois
University of Chicago Medicine
Committee on Clinical Pharmacology & Pharmacogenomics
Chicago, Illinois
Barbara Goldstein, MD, MMSc
Denver Arthritis Clinic
Physician
Denver, Colorado
Joshua J. Solomon, MD
National Jewish Health
Interstitial Lung Disease Program
Director
Denver, Colorado
National Jewish Health
Division of Pulmonary, Critical Care & Sleep Medicine
Professor of Medicine
Denver, Colorado